Reuters Indiaflipped into WorldMedical Journals Gilead study shows shorter 5-day course of remdesivir works as well as 10-day one Reuters India - By Deena Beasley(Reuters) - Gilead Sciences Inc, which has suggested that a shorter treatment duration could extend limited supplies of its drug remdesivir, on Wednesday published results of a study showing no significant
Bloomberg Lawflipped into Health Law + BusinessCoronavirus (Covid-19) Roche Partners With Gilead in Covid Trial of Drug Combination Bloomberg Law - By Tim Loh Roche Holding AGandGilead Sciences Inc.are initiating a late-stage trial of a two-drug combination in hopes of creating a new weapon in the battle …
The Economic Timesflipped into ET's Top StoriesManufacturing BDR Pharmaceuticals move on Remdesivir clone irks Gilead indiatimes.com - Teena Thacker New Delhi: BDR Pharmaceuticals, a Mumbai-based company, has sought the drug controller’s approval to manufacture and sell the generic version of …
Techdirtflipped into TechdirtMedicine Doctor With Rare Disease Crowdsourced His Own Cure, And Is Now Using That Network To Work On COVID-19 techdirt.com - Mike Masnick A recent episode of NPR's Fresh Air ran an amazing interview with Dr. David Fajgenbaum, who was diagnosed years ago with the rare Castleman's Disease, …
The Washington Postflipped into HealthCoronavirus (Covid-19) Administration initially dispensed scarce covid-19 drug to some hospitals that didn’t need it The Washington Post - Yasmeen AbutalebDemand for remdesivir soared after the National Institutes of Health announced on April 29 that a clinical trial had shown that hospitalized patients with advanced covid-19 who received the experimental
Genetic Engineering & Biotechnology Newsflipped into Genetic Engineering & Biotechnology NewsTechnology Phase III Trial to Study Combination of Genentech's Actemra, Gilead's Remdesivir vs. Severe COVID-19 Genetic Engineering & Biotechnology News - Alex Philippidis Genentech, a member of the Roche Group, said today its marketed arthritis drug Actemra® (tocilizumab) will be studied with Gilead Sciences’ antiviral …
